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A new copper(II) complex with formulae of [Cu(buobb)2](pic)2, where buobb stands for the ligand of 1,3-bis(1- butyl-
benzimidazol-2-yl)-2-oxopropane and pic represents 2,4,6-trinitrophenol, has been synthesized and characterized by elemental
analyses, molar conductivity, IR, UV-Vis spectra measurements, and cyclic voltammetry. The crystal structure of the copper(II)
complex has been determined by X-ray single-crystal diﬀraction. The coordination environment around each copper(II) atom
can be described as a distorted octahedral geometry. The π-π stacking interactions link the copper(II) complex into a 1D inﬁnite
network. The interactions of the ligand and the copper(II) complex with calf thymus DNA (CT-DNA) are investigated by using
electronic absorption titration, ethidium bromide-DNA displacement experiments, and viscosity measurements. Additionally, the
copper(II) complex’s antioxidant properties have been investigated in vitro.
1.Introduction
Recently, a lot of beautiful complexes of ingenious design
based on ﬂexible bis(imidazole) and bis(triazole) ligands
have been crystallographically characterized by diﬀerent
groups [1, 2]. However, bis(benzimidazole) ligands, which
represent a class of aromatic N-donor organic linkers, are
stilllessdeveloped[3,4].Benzimidazoleanditsderivativeare
an important class of aromatic heterocyclic compounds with
broad spectrum of biological activities such as antimicrobial
[5], anticancer [6], anti-inﬂammatory [7], antivirus [8],
anticonvulsant [9]. DNA is an important cellular receptor;
and many chemicals exert their antitumor eﬀects by binding
to DNA there by changing the replication of DNA and
inhibiting the growth of the tumor cells, which is the basis
of designing new and more eﬃcient antitumor drugs and
their eﬀectiveness depends on the mode and aﬃnity of the
binding [10, 11]. During the past decades, identifying small
molecules that are capable of binding to DNA through an
intercalation mode has attracted considerable interests [12].
Studies on the interaction of transition metal complexes
with nucleic acid have gained prominence, because of
their relevance in the development of new reagents for
biotechnology and medicine [13].
In previous papers, we investigated to a series of V-
shaped bis-benzimidazole ligands and their complex [14–
17]. In this study, a new ligand and its Cu(II) complex
have been synthesized and characterized. The DNA-binding
behaviors and antioxidation were investigated.
2. Experimental
2.1. Materials-Instrumentation-Physical Measurements. The
C, H, and N elemental analyses were determined using a
CarloErba1106elementalanalyzer.Electrolyticconductance
measurementsweremadewithaDDS-11Atypeconductivity
bridge using 10−3mol·L−1 solutions in DMF at room
temperature. The IR spectra were recorded in the 4000–
400cm−1 region with a Nicolet FT-VERTEX 70 spectrometer
using KBr pellets. A glassy carbon working electrode, a
platinum wire auxiliary electrode, and a saturated calomel
electrode (SCE) reference electrode were used in the three
electrode measurements. Electronic spectra were taken on2 Bioinorganic Chemistry and Applications
a Lab-Tech UV Bluestar spectrophotometer. 1H NMR spec-
tra were obtained with a Mercury plus 400MHz NMR
spectrometer with TMS as internal standard and DMSO-
d6 as solvent. The ﬂuorescence spectra were recorded on
a LS-45 spectroﬂuorophotometer. The antioxidant activities
containing the hydroxyl radical (OH•) and superoxide anion
radical (O2
−•) were performed in water bath with 722sp
spectrophotometer.
Calf thymus DNA (CT-DNA), ethidium bromide (EB),
nitroblue tetrazolium nitrate (NBT), methionine (MET),
and riboﬂavin (VitB2) were obtained from Sigma-Aldrich
Co. (USA). EDTA and safranin were produced in China.
Other reagents and solvents were reagent grade obtained
from commercial sources and used without further puriﬁ-
cation. Tris-HCl buﬀer, Na2HPO4–NaH2PO4 buﬀer, and
EDTA-Fe(II) solution were prepared using bidistilled water.
The stock solution of complex was dissolved in DMF at
3 × 10
−3 mol·L
−1. All chemicals used were of analytical
grade. The experiments involving interaction of the ligand
and the complex with CT-DNA were carried out in doubly
distilled water buﬀer containing 5mM Tris and 50 mM NaCl
and adjusted to pH 7.2 with hydrochloric acid. A solution
of CT-DNA gave a ratio of UV absorbance at 260 and
280nm of about 1.8-1.9, indicating that the CT-DNA was
suﬃciently free of protein [18]. The CT-DNA concentration
per nucleotide was determined spectrophotometrically by
employing an extinction coeﬃcient of 6600M−1cm−1 at
260nm [19].
2.1.1. DNA-Binding Studies. Absorption titration experi-
ments were performed with ﬁxed concentrations of the
compounds, while gradually increasing the concentration
of CT-DNA. To obtain the absorption spectra, the required
amount of CT-DNA was added to both compound solution
andthereferencesolutiontoeliminatetheabsorbanceofCT-
DNA itself. From the absorption titration data, the binding
constant (Kb) was determined using the equation [20]:
[DNA] 
εa −εf
 =
[DNA] 
εb −εf
 +
1
Kb

εb −εf
, (1)
where [DNA] is the concentration of CT-DNA in base
pairs, εa corresponds to the extinction coeﬃcient observed
(Aobsd/[M]), εf corresponds to the extinction coeﬃcient of
the free compound, εb is the extinction coeﬃcient of the
compound when fully bound to CT-DNA, and Kb is the
intrinsic binding constant. The ratio of slope to intercept in
the plot of [DNA]/(εa − εf) versus [DNA] gave the value of
Kb.
EB emits intense ﬂuorescence in the presence of CT-
DNA, due to its strong intercalation between the adjacent
CT-DNA base pairs. It was previously reported that the
enhanced ﬂuorescence can be quenched by the addition of a
secondmolecule[21,22].Theextentofﬂuorescencequench-
ing of EB bound to CT-DNA can be used to determine the
extent of binding between the second molecule and CT-
DNA. The competitive binding experiments were carried out
in the buﬀer by keeping [DNA]/[EB] = 1.13 and varying the
concentrations of the compounds. The ﬂuorescence spectra
of EB were measured using an excitation wavelength of
520nm, and the emission range was set between 550 and
750nm. The spectra were analyzed according to the classical
Stern-Volmer equation [23]:
I0
I
= 1+Ksv[Q],( 2 )
where I0 and I are the ﬂuorescence intensities at 599nm in
the absence and presence of the quencher, respectively, Ksv is
the linear Stern-Volmer quenching constant, and [Q] is the
concentration of the quencher. In these experiments, [CT-
DNA] = 2.5×10−3mol/L and [EB] = 2.2 × 10−3mol/L.
Viscosity experiments were conducted on an Ubbelohde
viscometer, immersed in a water bath maintained at 25.0 ±
0.1◦C. Titrations were performed for the compound (3μM),
and each compound was introduced into CT-DNA solution
(50μM) present in the viscometer. Data were presented
as (η/η0)
1/3 versus the ratio of the concentration of the
compound to CT-DNA, where η is the viscosity of CT-DNA
in the presence of the compound and η0 is the viscosity
of CT-DNA alone. Viscosity values were calculated from
the observed ﬂow time of CT-DNA containing solutions
corrected from the ﬂow time of buﬀer alone (t0), η = (t −t0)
[24].
2.1.2. Antioxidation Studies. T h eh y d r o x y lr a d i c a l si na q u e -
ous media were generated through the Fenton-type reaction
[25, 26]. The 3mL reaction mixtures contained 1.0mL of 40
ug/mL aqueous safranin, 1mL of 1.0mmol aqueous EDTA-
Fe(II), 1mL of 3% aqueous H2O2, and a series of quanti-
tatively microadding solutions of the tested compound. The
samplewithoutthetestedcompoundwasusedasthecontrol.
The reaction mixtures were incubated at 37◦Cf o r3 0 m i n
in a water-bath. Absorbance at 520nm was measured, and
the solvent eﬀect was corrected throughout. The scavenging
eﬀect for OH• was calculated from the following expression:
Scavenging eﬀect % =

Asample −Ar

(Ao −Ar)
×100%, (3)
where Asample is the absorbance of the sample in the presence
of the tested compound, Ar is the absorbance of the blank in
theabsenceofthetestedcompound,andAo istheabsorbance
in the absence of the tested compound and EDTA-Fe(II)
[27].
A nonenzymatic system containing 0.5mL 3.3 × 10−5 M
VitB2,1 m L2 . 3× 10−4 M NBT, 1mL 0.05M MET, and
2.5mL 0.067M phosphate buﬀer (Na2HPO4–NaH2PO4,
pH = 7.8) was used to produce superoxide anion (O2•−),
and the scavenging rate of O2•− under the inﬂuence of 0.3–
3.0μM tested compound was determined by monitoring the
reduction in rate of transformation of NBT to monofor-
mazan dye [28]. The reactions were monitored at 560nm
with a UV-Vis spectrophotometer, and the rate of absorption
change was determined. The percentage inhibition of NBT
reduction was calculated using the following equation [29]:
percentage inhibition of NBT reduction = (1 − k /k) ×
100, where k  and k present the slopes of the straightBioinorganic Chemistry and Applications 3
line of absorbance values as a function of time in the
presence and absence of SOD mimic compound (SOD is
superoxide dismutase), respectively. The IC50 values for
the complexes were determined by plotting the graph of
percentage inhibition of NBT reduction against the increase
in the concentration of the complex. The concentration of
the complex which causes 50% inhibition of NBT reduction
is reported as IC50.
2.2. Synthesis of the Ligand and Complex
2.2.1. 1,3-Bis(1-butylbenzimidazol-2-yl)-2-oxopropane (bu-
obb). The 1,3-bis(1-benzimidazol-2-yl)-2-oxopropane (5.56
g, 0.020mol) (synthesized by the literature method [30])
was suspended in dry tetrahydrofuran (170mL) and stirred
under reﬂux with potassium (1.56g). Iodobutane (4.84g,
0.040mol) was added; the solution was stirred for 2h. The
solvents were stripped to dryness and the resulting powder
dissolved in distilled water. The soluble KI was removed
by ﬁltration. The undissolved substances were recrystallized
from MeOH, and a colorless powder was deposited. Yield:
4.13g (53%); m.p. 70–71◦C. Anal. Calcd. for C24H30N4O
(Mr = 390): C 73.81; H 7.74; N 14.35%; found: C 73.83;
H 7.72; N 14.37%. 1H NMR ([D6]DMSO, 400MHz): δ =
7.55–7.65 (m, 4 H, Ph-H), 7.17–7.31 (m, 4 H, Ph-H), 4.87(s,
4H ,C H 2), 4.19–4.26 (m, 4 H, CH2), 1.64–1.71 (m, 4 H,
CH2), 1.18–1.29 (m, 4 H, CH2), 0.75–0.89 (m, 6 H, CH3).
IR (selected data, KBr ν/cm−1): ν = 750 (νo–Ar), 1060 (νC–O),
1460 (νC=N), 1614 (νC=C). UV/Vis (DMF): λ = 280, 288nm.
ΛM (DMF, 297K): 0.87S·cm2·mol−1.
2.2.2. Preparation of Cu(II) Complex. To a stirred solution of
1,3-bis(1-butylbenzimidazol-2-yl)-2-oxopropane (0.156g,
0.40mmol) in hot MeOH (5mL) was added Cu(II) picrate
(0.104g, 0.20mmol) in MeOH (5mL). A deep brown
crystalline product formed rapidly. The precipitate was
ﬁltered oﬀ, washed with MeOH and absolute Et2O, and
dried in vacuo. The dried precipitate was dissolved in DMF
resulting in a brown solution. The brown crystals suitable
for X-ray diﬀraction studies were obtained by ether diﬀusion
into DMF after several days at room temperature. Yield:
0.170g (58.7%). Anal. Calcd. for C66H78Cu N16O18 (Mr =
1446.98): C, 54.78; H, 5.43; N, 15.49. Found (%): C, 54.77;
H, 5.44; N, 15.50. Selected IR data (KBr ν/cm−1): 748 (νo–Ar),
1099 (νC–O), 1494 (νC=N), 1631 (νC=C). UV/Vis (DMF):
λ = 281, 288. Λ M (DMF, 297K): 100.88S·cm2·mol−1.
2.2.3. X-Ray Crystal Structure Determination. A suitable
single crystals were mounted on a glass ﬁber, and the
intensity data were collected on a Bruker Apex-II CCD
(Japan) diﬀractometer with graphite-monochromatized Mo
Kα radiation (λ = 0.71073 ˚ A) at 296(2) K. Data reduction
and cell reﬁnement were performed using Saint programs
[31]. The absorption correction was carried out by empirical
methods. The structure was solved by direct methods
and reﬁned by full-matrix least squares against F2 using
Shelxtl software [32]. All H atoms were found in diﬀerence
electron maps and were subsequently reﬁned in a riding
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Figure 1: Cyclic voltammogram of the Cu(II) complex recorded
with a platinum electrode in DMF solution containing (n-
Bu)4N·ClO4 (0.1 M). (Scan rate = 0.05V·s−1).
N1
N2
N3
N4
N5
N6
N7
N8
01
02
Cu1
Figure 2: Molecular structure of the [Cu(buobb)2]2+ cation with
displacement ellipsoids drawn at the 30% probability level; H
atoms, trinitrophenol anions and DMF are omitted for clarity.
model approximation with C–H distances ranging from 0.95
to 0.99 ˚ A. The crystal data and experimental parameters
relevant to the structure determination are listed in Table 1.
Selected bond distances and angles are presented in Table 2.
3. Results and Discussion
3.1. Characterization of the Complex. The ligand buobb and
the Cu(II) complex are very stable in the air. The ligand
is soluble in organic solvents but insoluble in water. The
Cu(II) complex is soluble in DMF and DMSO but insoluble
in water and other organic solvents, such as methanol,4 Bioinorganic Chemistry and Applications
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Figure 3: The structure of complex linked via π-π stacking interaction.
Table 1: Crystallographic data for [Cu(buobb)2](pic)2·2DMF.
Compound [Cu (buobb2)2](pic)2·2DMF
Molecular formula C66H78CuN16O18
Molecular weight 1446.98
Crystal system Triclinic
Space group P-1
a (˚ A) 14.0047 (14)
b (˚ A) 16.1337 (17)
c (˚ A) 16.6316 (17)
α (◦) 70.8150 (10)
β (◦) 78.0420 (10)
γ (◦) 74.7260 (10)
V (˚ A3) 3393.7 (6)
Z 2
ρcald (mg·m−3)
Absorption coeﬃcient (mm−1)
1.416
0.406
F (000) 1518
Crystal size (mm) 0.35 × 0.31 × 0.29
θ range for data collection (◦) 1.52 to 25.00
h/k/l (max, min)
−16 ≤ h ≤ 16, −19 ≤ k ≤
19, −19 ≤ l ≤ 19
Reﬂections collected 24488
Independent reﬂections 11850
Reﬁnement method Full-matrix least squares on F2
Data/restraints/parameters 11850/14/918
Goodness of ﬁt on F 2 1.044
Final R1, wR2 indices [I>2σ(I)] R1 = 0.0837, wR2 = 0.2320
R1, wR2 indices (all data) R1 = 0.1184, wR2 = 0.2701
Largest diﬀerences peak and hole
(e˚ A−3) 1.107 and −0.658
ethanol, acetone, petroleum ether, trichloromethane, and
so forth. The results of the elemental analyses show that
the composition is [Cu(buobb)2](pic)2·2DMF. The value
of molar conductance shows that the complex is a 1:2
electrolyte in DMF [33].
The IR spectra of the free ligand and the Cu(II)
complex were compared. The IR spectrum of the complex
shows that the strong absorption νC=N in the free ligand is
shifted to lower wave numbers in the Cu(II) complex. The
redshift indicates that the nitrogen atoms of the ligands are
coordinated to the copper (II) ions. They are the preferred
nitrogen atoms for coordination, as found in other metal
complexes with benzimidazole open chain crown ether
derivatives [34]. This fact agrees with the result determined
by X-ray diﬀraction. In the UV/Vis spectra, the band of free
ligand is red shifted in the complex and shows clear evidence
of C=N coordination to the copper atom. The absorption
band is assigned to π-π∗ (imidazole) transition [35].
The electrochemical properties of the complex were
studied by cyclic voltammetry (CV) in DMF. The voltammo-
gram is shown in Figure 1. The Cu(II) complex exhibits a
pair of cathodic and anodic waves. The separation between
the cathodic and anodic peak potentials ΔEp (ΔEpa − Epc)
and the current I (ipa/ipc) indicates a semireversible redox
process assignable to the CuII/CuI couple [36]. The neutral
uncomplexed ligand buobb is proved not to be electroactive
over the range −1.3 to +1.3V. According to previous reports
[37], a transition metal complex must have a reduction
potential below 0.65V [E◦ (
1O2–O2
−)] and above −0.33V
[E◦ (O2–O2
−)] such that catalysis can take place to be an
eﬀective mimic of superoxide dismutase but toxic single
oxygen cannot be formed; so the redox potential 0.139V
shows that the complex has SOD activity.
3.2. Description of the Structure of the Complex. Complex
crystallizes in the Triclinic space group P-1, and its struc-
ture along with the atomic numbering scheme is shown
in Figure 2, consisting of a [Cu(buobb)2]2+ cation, two
trinitrophenol anions, and two DMF. The central metal ion
of [Cu(buobb)2]2+ cation, adopting a distorted octahedralBioinorganic Chemistry and Applications 5
265 270 275 280 285
0.27
0.3
0.33
0.36
0.39
A
b
s
o
r
b
a
n
c
e
Wavelength (nm)
(a)
2468 1 0 1 2 1 4 1 6
3.5
4
4.5
5.0
5.5
6
6.5
Kb = 6.4 ×103M−1
R2 = 0.972
×105(M) [DNA]
{
[
D
N
A
]
/
(
ε
A
−
ε
f
)
}
×
1
0
8
(
M
2
c
m
)
(b)
250 260 270 280 290 300
0.6
0.8
1
1.2
A
b
s
o
r
b
a
n
c
e
Wavelength (nm)
(c)
2468 1 0 1 2 1 4 16
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Kb = 1×105M−1
R2 = 0.991
×105(M)
0
[DNA]
{
[
D
N
A
]
/
(
ε
A
−
ε
f
)
}
×
1
0
8
(
M
2
c
m
)
(d)
Figure 4: Electronic spectra of the free ligand buobb (a) and the complex Cu(II) (c) in Tris-HCl buﬀer upon addition of CT-DNA. The
arrow shows the emission intensity changes upon increasing DNA concentration. [DNA]/(εa − εf) versus [DNA] for the titration of the
ligand buobb (b) and the complex Cu(II) (d) with CT-DNA.
Table 2: Selected bond lengths (˚ A) and angles (◦) for [Cu(buobb)2](pic)2·2DMF.
Bond lengths
Cu(1)–N(1) 1.973(4) Cu(1)–N(3) 2.032(4)
Cu(1)–N(5) 1.998(4) Cu(1)–N(7) 1.993(4)
Cu(1)–O(1) 2.486(3) Cu(1)–O(2) 2.492(4)
Bond angles
N(1)–Cu(1)–N(7) 90.69(15) N(1)–Cu(1)–N(5) 167.90(17)
N(7)–Cu(1)–N(5) 89.86(15) N(1)–Cu(1)–N(3) 89.82(15)
N(7)–Cu(1)–N(3) 165.70(17) N(5)–Cu(1)–N(3) 92.62(15)
N(1)–Cu(1)–O(1) 74.27(14) N(7)–Cu(1)–O(1) 118.65(14)
N(5)–Cu(1)–O(1) 94.90(14) N(3)–Cu(1)–O(1) 75.17(14)
N(1)–Cu(1)–O(2) 116.15(15) N(7)–Cu(1)–O(2) 74.50(14)
N(5)–Cu(1)–O(2) 75.59(14) N(3)–Cu(1)–O(2) 92.49(14)
O(1)–Cu(1)–O(2) 164.24(11)6 Bioinorganic Chemistry and Applications
580 590 600 610 620
550
600
650
700
750
800
I
n
t
e
n
s
i
t
y
(
a
.
u
.
)
Wavelength (nm)
(a)
01234
0.98
0.99
1
1.01
1.02
[Complex]×105(M)
I
0
/
I
Ksv = 9.3 ×102
R2 = 0.96
(b)
560 580 600 620 640
200
300
400
500
600
700
I
n
t
e
n
s
i
t
y
(
a
.
u
.
)
Wavelength (nm)
(c)
0123456
1
1.1
1.2
1.3
1.4
×105(M)
I
0
/
I
Ksv = 6.7 ×103
R2 = 0.958
[Complex]
(d)
Figure 5: Emission spectra of EB bound to CT-DNA in the presence of the free buobb (a) and the Cu(II) complex (c), λex = 520nm.
The arrows show the intensity changes upon increasing concentrations of the complexes. Fluorescence quenching curves of EB bound to
CT-DNA by the free buobb (b) and the Cu(II) complex (d). (Plots of I0/I versus [Complex]).
geometry,issixcoordinatedwithanN4O2 ligandsetinwhich
four N atoms (N(1), N(3), N(5), and N(7)) are aﬀorded
by the benzimidazole rings and other two O atoms (O(1)
and O(2)) are supplied by the buobb. An equatorial plane is
formed by atoms N1, N3, N5, N7, and Cu1, where the largest
deviation for N7 atom is 0.233 ˚ A and the deviation for the
Cu(1) atom is 0.021 ˚ A from the mean plane. The bond angles
of ideal 90◦ are range from 89.82(15) [N(1)–Cu(1)–N(3)]
to 90.69(15) N(1)–Cu(1)–N(7) and from 92.49(14) N(3)–
Cu(1)–O(2) to 75.17(14) N(3)–Cu(1)–O(1). With regard to
a regular octahedron, the angles show a certain distortion.
The benzimidazole rings from the adjacent units arrange in
an oﬀset face-to-face fashion with the vertical distance of
center to center 3.780 ˚ A and 3.717 ˚ A, suggesting signiﬁcant
π-π stacking interactions (Figure 3). Thus, the units are
stacked together eﬃciently via the π-π stacking interactions
of benzimidazole.
3.3. DNA-Binding Properties
3.3.1. Absorption Spectroscopic Studies. The electronic ab-
sorption spectra of the ligand and the Cu(II) complex in
the absence and presence of CT-DNA are given in Figure 4.
As seen from Figure 4(a), there exists a band at 277nm
for the free ligand, and in Figure 4(c) a band is at 278nm
for the Cu(II) complex. With increasing concentrations
of CT-DNA, the absorption bands of the free ligand at
277nm exhibited hypochromism of 18.3%. For the Cu(II)Bioinorganic Chemistry and Applications 7
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Figure 6: Eﬀect of increasing amounts of the compounds on the
relative viscosity at 25.0 ± 0.1◦C.
complex, the absorption band at 278nm appeared with
hypochromism of 32.1%. The hypochromisms observed for
the bands of the free ligand and its Cu(II) complex are
accompanied. The electronic absorption spectroscopy is one
of the most useful techniques in DNA binding studies of
metal complexes [38–40]. A compound binding to DNA
through intercalation usually results in hypochromism due
to the intercalation mode involving a strong π-π stacking
interactionbetweenthearomaticchromophoreandtheDNA
base pairs. It seems to be generally accepted that the extent
of the hypochromism in the UV-vis band is consistent with
the strength of intercalative interaction [41]. So, the above
phenomena imply that the compounds interact with CT-
DNAquiteprobablybyintercalatingintotheDNAbasepairs.
From the results of electronic absorption spectroscopy, the
Kb values of the free ligand buobb and the Cu(II) complex
were 6.4 × 103 M−1 (R2 = 0.972 for 13 points) and 1.0
× 105 M−1 (R2 = 0.991 for 10 points), respectively. We
can conclude that the free ligand buobb and the Cu(II)
complex can interact with CT-DNA through the same mode
(intercalation). In general, this may be attributed to the
Cu(II) complex with the electric eﬀect and steric hindrance
resulting in the relatively close stacking between the Cu(II)
complex and the DNA base pairs [42, 43].
3.3.2. Fluorescence Spectroscopic Studies. I no r d e rt oe x a m i n e
the ability of the compounds to displace EB (=3,8-Diamino-
5-ethyl-6-phenyl-phenanthridinium bromide) from its EB-
DNA complex, a competitive EB binding study has been
undertaken with UV-vis and ﬂuorescence experiments [44,
45]. EB, a phenanthridine ﬂuorescence dye, is a typical
indicator of intercalation [46] that forms soluble complexes
with nucleic acids and emits intense ﬂuorescence in the
presence of CT DNA due to the intercalation of the planar
phenanthridine ring between adjacent base pairs on the
double helix. The changes observed in the spectra of EB on
its binding to CT DNA are often used for the interaction
study between DNA and other compounds, such as metal
complexes [47]. The ligand buobb and the Cu(II) complex
show no ﬂuorescence at room temperature in solution or in
the presence of CT-DNA, and their binding to DNA cannot
be directly predicted through the emission spectra. However,
competitive EB binding studies could be undertaken in
order to examine the binding of each compound with
DNA. EB does not show any appreciable emission in buﬀer
solution due to ﬂuorescence quenching of the free EB by
the solvent molecules. Upon addition of the ligand or
complex to a solution containing EB, neither quenching of
free EB ﬂuorescence has been observed, nor new peak in
the spectra appeared. The ﬂuorescence intensity is highly
enhanced upon addition of CT-DNA, due to its strong
intercalation with DNA base pairs. Addition of a second
molecule, which may bind to DNA more strongly than EB,
results in a decrease in the DNA-induced EB emission due
to the replacement of EB or to electron transfer [48]. The
addition of the compounds results in a signiﬁcant decrease
of the ﬂuorescence intensity of the emission band of the
DNA-EB system at 599nm indicating the competition of
the compounds with EB in binding to DNA. The observed
quenching of DNA-EB ﬂuorescence for the ligand or their
complex suggests that they displace EB from the DNA-EB
complex and they can interact with CT DNA probably by
the intercalative mode. The Stern-Volmer plots of DNA-EB
(Figure 5) illustrate that the quenching of EB bound to DNA
by the compounds with the linear Stern-Volmer equation,
which proves that the replacement of EB bound to DNA
by each compound results in a decrease in the ﬂuorescence
intensity. The Ksv values of the ligand buobb and the Cu(II)
complexshowthattheycandisplaceEBandbindtotheDNA
[44, 45]. The Ksv values for the ligand buobb and the Cu(II)
complex are 9.2 × 102 M−1 (R2 = 0.960 for 6 points) and
6.7 × 103 M−1 (R2 = 0.958 for 6 points), respectively. The
data suggest the interaction. Moreover, the binding strength
of Cu(II) complex is greater than the free ligand.
3.3.3. Viscosity Measurements. Optical photophysical tech-
niques are widely used to study the binding model of
the ligand, metal complexes, and DNA, but do not give
suﬃcient clues to support a binding model. Therefore,
viscositymeasurementswerecarriedouttofurtherclarifythe
interaction of metal complexes, and DNA. Hydrodynamic
measurements that are sensitive to the length change (i.e.,
viscosity and sedimentation) are regarded as the least
ambiguous and the most critical tests of a binding model
in solution in the absence of crystallographic structural data
[49, 50]. For the ligand buobb and the Cu(II) complex, with
increasing the amounts of compounds, the viscosity of DNA
increasessteadily.Thevaluesof(η/η0)
1/3 wereplottedagainst
[compound]/[DNA] (Figure 6). In classical intercalation,
the DNA helix lengthens as base pairs are separated to
accommodate the bound ligand leading to increased DNA
viscosity whereas a partial, nonclassical ligand intercalation
causes a bend (or kink) in DNA helix reducing its eﬀective8 Bioinorganic Chemistry and Applications
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Figure 7: Plots of antioxidation properties for the Cu(II) complex. (a) Represents the hydroxyl radical scavenging eﬀect (%) for the Cu(II)
complex. (b) Represents the superoxide radical scavenging eﬀect (%) for the Cu(II) complex.
length and thereby its viscosity [49]. The eﬀects of the ligand
and the Cu(II) complex on the viscosity of CT-DNA are
shown in Figure 6. The viscosity of CT-DNA is increased
steadily with the increment of the ligand buobb and the
Cu(II) complex, and it is further illustrated that the ligand
buobb and the Cu(II) complex intercalate with CT-DNA
[49]. The results from the viscosity experiments conﬁrm the
mode of these compounds intercalating into DNA base pairs
and already established through absorption spectroscopic
studies and ﬂuorescence spectroscopic studies.
3.4. Antioxidant Activity
3.4.1. Hydroxyl Radical Scavenging Activity. Figure 7(a)
depicts the inhibitory eﬀect of the Cu(II) complex on OH•
radicals. The inhibitory activity of the Cu(II) complex is
marked, and the suppression ratio increases with increasing
concentration of the test Cu(II) complex. We compared the
present complex with the well-known natural antioxidants
mannitol and vitamin C, using the same method as reported
in a previous paper [50]. The 50% inhibitory concentration
(IC50) value of mannitol is about 9.6μM. According to the
antioxidant experiments, the IC50 of the Cu(II) complex is
2.88μM(Figure7(a)),whichimpliesthattheCu(II)complex
exhibits the ability to scavenge hydroxyl radical as well as
mannitolandvitaminC.ThismaybeattributedtotheCu(II)
ion’s valence alternation [51, 52].
3.4.2. Superoxide Radical Scavenging Activity. We have exam-
ined the SOD activity of complex using the xanthine/
xanthineoxidaseassayduetotheirconducivesolubility.SOD
activity was monitored by reduction of nitro blue tetra-
zolium (NBT) with O2
−• generated by xanthine/xanthine
oxidase system. As the reaction proceeds, the farmazan
color is developed and a color change from colourless to
blue appeared which was associated with an increase in
the absorbance at 560nm. Figure 7(b) shows the plot of
superoxide radical scavenging eﬀects (%) for the Cu(II)
complex. The ligand does not have antioxidant activity; the
values of IC50 of the Cu(II) complex for O2
−• are 1.26μM.
Theseresultssuggestthatcomplexshowsstrongerscavenging
eﬀects than the free ligand buobb for O2
−•. We suggest that
the mechanism of action of the Cu(II) complex involves
the redox process. The IC50 values for [Cu(salicylate)2],
[Cu(NA/Sal)] (NA/Sal = nicotinic-salicylic acid), CuSO4,
and the native Cu, Zn-SOD [53, 54]a r e1 6μM, 42.79μM,
30μM, and 0.04μM, respectively. The IC50 values for the
copper complex was better than the values reported for
[Cu(salicylate)2], [Cu(NA/Sal)], and CuSO4, less than native
Cu, Zn-SOD. The results and the electrochemical properties
are consistent.
4. Conclusion
Taken together, a new bis-benzimidazole base ligand and
its Cu(II) complex were reported. The structure of the
ligand and the Cu(II) complex were determined on the
basis of elemental analyses, molar conductivities, IR spectra,
1H NMR, and UV-vis spectra. Cu(II) complex’s crystal
structure has been determined by X-ray crystallography
method. Experimental results indicate that the ligand and
the Cu(II) complex bind to DNA via an intercalation
mode and the Cu(II) complex can bind to DNA more
strongly than the free ligand alone. Moreover, the Cu(II)
complex has better antioxidant activity than the ligand.
Results obtained from our present work would be useful
to understand the mechanism of interactions of the small
molecule compounds binding to DNA and helpful in the
development of their potential biological, pharmaceutical,
and physiological implications in the future.Bioinorganic Chemistry and Applications 9
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